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Objectives The aim of this study was to determine the economic impact of several anticoagulation strategies for moderate-
and high-risk non–ST-segment elevation acute coronary syndrome (NSTE-ACS) patients managed invasively.
Background The ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial demonstrated that bivalirudin
monotherapy yields similar rates of ischemic complications and less bleeding than regimens incorporating glyco-
protein IIb/IIIa receptor inhibitors (GPI) for moderate- and high-risk NSTE-ACS.
Methods In ACUITY, 7,851 U.S. patients were randomized to: 1) heparin (unfractionated or enoxaparin)  GPI; 2) bivalirudin 
GPI; or 3) bivalirudin monotherapy. Patients assigned to GPI were also randomized to upstream GPI before catheter-
ization or selective GPI only with percutaneous coronary intervention. Resource use data were collected prospectively
through 30-day follow-up. Costs were estimated with standard methods including resource-based accounting, hospital
billing data, and the Medicare fee schedule.
Results At 30 days, ischemic events were similar for all groups. Major bleeding was reduced with bivalirudin mono-
therapy compared with heparin  GPI or bivalirudin  GPI (p  0.001). Length of stay was lowest with bivaliru-
din monotherapy or bivalirudin  catheterization laboratory GPI (p  0.02). Despite higher drug costs, aggregate
hospital stay costs were lowest with bivalirudin monotherapy (mean difference range: $184 to $1,081, p 
0.001 for overall comparison) and at 30 days (mean difference range: $123 to $938, p  0.005). Regression
modeling demonstrated that hospital savings were primarily due to less major and minor bleeding with bivaliru-
din ($8,658/event and $2,282/event, respectively).
Conclusions Among U.S. patients in the ACUITY trial, bivalirudin monotherapy compared with heparin  GPI resulted in simi-
lar protection from ischemic events, reduced bleeding, and shorter length of stay. Despite higher drug costs, ag-
gregate hospital and 30-day costs were lowest with bivalirudin monotherapy. Thus bivalirudin monotherapy
seems to be an economically attractive alternative to heparin  GPI for patients with moderate- and high-risk
NSTE-ACS. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes [ACS]; NCT00093158) (J Am
Coll Cardiol 2008;52:1758–68) © 2008 by the American College of Cardiology Foundation
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November 25, 2008:1758–68 Cost-Effectiveness of Bivalirudin in ACShe ACUITY (Acute Catheterization and Urgent Inter-
ention Triage Strategy) trial investigated whether antithrom-
otic therapy with bivalirudin—either alone (monotherapy) or
n conjunction with a parenteral glycoprotein IIb/IIIa receptor
ntagonist (GPI)—could yield improved outcomes for a broad
opulation of patients with moderate- and high-risk acute
oronary syndrome (ACS) undergoing an early invasive
trategy (1). The overall results of the ACUITY trial
emonstrated that bivalirudin monotherapy was statistically
oninferior to heparin  GPI and bivalirudin  GPI in
erms of ischemic complications but was associated with
ubstantially lower rates of bleeding complications. How-
ver, the economic impact of using bivalirudin in this setting
emains unknown. In particular, there has been concern that
rolonged periods of pre-treatment before performance of
ardiac catheterization and revascularization could lead to
ubstantially higher costs with this novel therapy.
We therefore performed a prospective economic evalua-
ion, from the perspective of the U.S. health care system, in
onjunction with the ACUITY trial. The objectives of the
tudy were: 1) to compare the in-hospital and 30-day costs
f using bivalirudin monotherapy with those of heparin 
PI or bivalirudin  GPI among patients with ACS
ndergoing an early invasive strategy; and 2) to explore the
mpact of both ischemic and bleeding complications on the
ost of care for this common condition.
ethods
atient population and treatment protocol. Between Au-
ust 2003 and December 2005, 13,819 patients were en-
olled in the ACUITY trial. As specified in the study
rotocol, the economic analysis was confined to those
atients enrolled at U.S. treatment sites (n  7,851). The
CUITY study design has been described previously (2).
riefly, ACUITY was a prospective, open-label, random-
zed, multicenter trial comparing 3 antithrombotic regi-
ens: heparin (unfractionated heparin [UFH] or low-
olecular weight heparin [LMWH]) GPI (standard care
roup), bivalirudin  GPI, or bivalirudin monotherapy.
atients assigned to heparin  GPI or bivalirudin  GPI
ere also randomly assigned again in a factorial design to
outinely receive GPI immediately after randomization (the
upstream” group) or to selective deferred treatment with
PI starting in the catheterization laboratory, for use only
n patients undergoing percutaneous coronary intervention
PCI). The study protocol was approved by the institutional
eview board at each site, and each patient provided in-
ormed consent before enrollment.
The UFH and LMWH were administered as standard,
eight-adjusted doses as per current guidelines (3). Biva-
irudin was begun before angiography, with an intravenous
olus of 0.1 mg/kg and an infusion of 0.25 mg/kg/h. Before
CI, an additional intravenous bolus of 0.5 mg/kg was
dministered, and the infusion was increased to 1.75 mg/
g/h (2). Patients assigned to receive GPI could receive pither eptifibatide or tirofiban
efore catheterization or eptifi-
atide or abciximab at the time
f PCI (in their approved doses).
mong patients assigned to biva-
irudin monotherapy, provisional
PI could be administered at the
perator’s discretion to treat po-
ential thrombotic complications.
ll patients received aspirin before
CI, and pre-treatment with clo-
idogrel (300 mg) was encour-
ged. After PCI, all patients re-
eived aspirin indefinitely 
lopidogrel (75 mg/day) for at least
0 days (1 year recommended).
ssessment of in-hospital out-
omes and clinical follow-
p. Baseline characteristics, pro-
edural details, and clinical outcomes during the initial
ospital stay and 30-day follow-up period were recorded on
tandardized case report forms. All primary end point
vents, including death, myocardial infarction (MI), un-
lanned revascularization, and major bleeding, were adjudi-
ated according to predefined criteria by a blinded indepen-
ent committee with original source documentation (2).
omposite ischemia was defined as death, MI, or un-
lanned revascularization.
Major bleeding (ACUITY scale) was defined as intracra-
ial bleeding, intraocular bleeding, access site hemorrhage
equiring intervention, 5 cm diameter hematoma, reduc-
ion in hemoglobin concentration of 4 g/dl without an
vert source of bleeding, reduction in hemoglobin concen-
ration of 3 g/dl with an overt source of bleeding,
eoperation for bleeding, or use of any blood product
ransfusion. Bleeding events attributable to coronary artery
ypass graft surgery (CABG) were excluded (2).
etermination of medical care costs. Medical care costs
or the initial hospital stay and for the 30-day follow-up period
ere assessed for all patients from the perspective of the U.S.
ealth care system with a combination of resource-based costs
nd hospital billing data, as previously described (4). Costs
ere expressed in 2005 U.S. dollars, and discounting was not
erformed, given the brief time horizon of the analysis.
ardiac catheterization laboratory costs. Detailed re-
ource use was recorded for each procedure, and the cost of
ach item was estimated on the basis of the mean hospital
cquisition cost for the item in 2005. Costs for antithrombotic
gents (bivalirudin, tirofiban, eptifibatide, abciximab, LMWH,
nd UFH) were based on the actual measured bolus and
nfusion volumes and current average wholesale prices, assum-
ng that partially unused vials would be discarded. Costs of
ivalirudin were $412/vial, abciximab $504/vial, eptifibatide
68/bolus vial and $214/infusion vial, and tirofiban $425/vial.
osts of additional disposable equipment, overhead, and de-
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft surgery
GPI  glycoprotein IIb/IIIa
receptor antagonist
LMWH  low-molecular
weight heparin
LOS  length of stay
MI  myocardial infarction
NSTE-ACS  non–ST-
segment elevation acute
coronary syndrome
PCI  percutaneous
coronary intervention
UFH  unfractionated
heparinreciation for the cardiac catheterization laboratory were esti-
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Cost-Effectiveness of Bivalirudin in ACS November 25, 2008:1758–68ated on the basis of the average cost/procedure at Beth Israel
eaconess Medical Center in 2005 and then adjusted for
ctual procedure duration.
ther costs. All other hospital costs were determined with
top-down” accounting methods based on each hospital’s
edicare cost report (4). For approximately 3,000 randomly
elected patients, itemized bills were obtained for the initial
ospital stay and any subsequent cardiovascular hospital stays
uring the follow-up period. In addition, we obtained billing
ata for all patients who experienced a major in-hospital
omplication. Hospital costs were then determined by multi-
lying itemized hospital charges by the cost-center specific
ost-to-charge ratio obtained from the hospital’s Medicare cost
eport as previously described (5,6). For those admissions for
hich billing data were not collected (n  4,808), non-
rocedural hospital costs were imputed on the basis of a linear
egression model developed with the hospital admissions for
hich complete billing information was available (n 3,615).
ndependent variables for this model included length of stay
LOS), intensive care unit LOS, in-hospital complications,
nd revascularization procedures (model R2  0.75).
Physician costs for inpatient services, procedures, and
iagnostic tests were estimated on the basis of the 2005
edicare Fee Schedule. Costs for outpatient medical ser-
ices and medications were not assessed due to the short
uration of follow-up for the economic analysis.
tatistical analysis. Although the primary clinical analysis
ompared outcomes across 3 treatment groups (heparin 
PI, bivalirudin  GPI, and bivalirudin monotherapy) and
ooled data for routine upstream and deferred selective
atheterization laboratory-based GPI regimens, we hypoth-
sized that use of upstream GPI would add significantly to
reatment costs. Therefore, we analyzed costs separately for
ach of the 5 arms: 1) heparin upstream GPI; 2) heparin
atheterization laboratory GPI; 3) bivalirudin  upstream
PI; 4) bivalirudin  catheterization laboratory GPI; and
) bivalirudin monotherapy. The pre-specified primary end
oint of the economic study was total 30-day costs. In
ddition, a secondary end point of index hospital costs was
xamined to consider the perspective of a typical hospital
hat is reimbursed for each episode of care.
To reduce the impact of high-cost outliers on group
eans, it was pre-specified in the study protocol that
n-hospital and 30-day costs greater than the 99th percentile
or each treatment group would be assigned costs equal to
he 99th percentile for the group. Discrete data are reported
s frequencies; continuous data are reported as mean  SD.
ost data are reported as both mean and median values.
iscrete variables were compared by the Fisher exact test.
ormally distributed continuous variables were compared
y analysis of variance. Non-normally distributed data
ncluding cost and LOS were compared by the Kruskall-
allis test. Confidence intervals for cost differences were
stimated with bootstrap resampling with bias correction
1,000 replicates) (7). All statistical analyses were performed
ccording to the intention-to-treat principle. pMultiple linear regression was performed to identify
ndependent predictors of initial hospital costs. Candidate
ariables for this analysis included patient characteristics,
schemic complications, repeat procedures, and bleeding
omplications as defined in the protocol. Because the goal of
his analysis was explanatory rather than predictive, inter-
ediate variables (including LOS) were not considered for
hese models. Untransformed cost was used as the depen-
ent variable for these analyses for ease of interpretation and
ecause model fit did not improve appreciably with log-
ransformed costs. Attributable costs were calculated by
ultiplying the independent cost of each event (derived
rom the regression model coefficients) by its frequency in
he treatment group. The absolute cost savings associated
ith prevention of specific clinical events were estimated by
ultiplying the independent cost of each event by the
ifference in event frequency between the experimental (i.e.,
ivalirudin) and standard care (i.e., heparin  GPI) groups.
esults
atient population. Baseline characteristics of the popula-
ion for the economic substudy (i.e., the U.S. cohort) are
ummarized in Table 1. Among the 5 treatment groups,
atient characteristics were generally comparable in terms of
emographic characteristics, disease history, and presenting
linical features. Overall, approximately 50% of patients
ere biomarker positive at the time of enrollment and 87%
ad Thrombolysis In Myocardial Infarction risk score 3.
oronary angiography was performed in 99% of patients,
ith a median time from randomization to angiography of
.2 h (mean 10.2 h). Approximately one-third of patients
ad a time from randomization to angiography of 9 h.
he intended revascularization strategy was also similar
cross the 5 treatment groups, including planned PCI in
3% to 57% and planned CABG in 11% to 13%.
esource use, outcomes, and costs. In-hospital resource
se for the study cohort is summarized in Table 2. In
eneral, most patients received only the assigned antithrom-
otic regimen, although approximately 2% of patients in the
eparin  GPI groups also received open-label bivalirudin.
he use of provisional GPI therapy either before coronary
ngiography (because of refractory ischemia) or during PCI
because of thrombotic complications) occurred in 7.6% of
atients in the bivalirudin monotherapy group. The cost of
nticoagulants differed significantly across the 5 treatment
roups (p  0.001) and was lowest for patients assigned to
eparin  catheterization laboratory GPI (mean cost 
515/patient; median  $399) and highest for patients
ssigned to bivalirudin  upstream GPI (mean  $1,537;
edian  $1,192). For patients treated with initial PCI,
here were no other significant differences in procedural
esource use, including procedure duration, contrast volume,
nd number and type of stents implanted. Reanalysis of
osts including those patients with costs above the 99th
ercentile and below the 1st percentile did not alter the cost
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November 25, 2008:1758–68 Cost-Effectiveness of Bivalirudin in ACSankings across treatment groups or the statistical signifi-
ance of the comparisons.
Consistent with the results of the overall clinical trial,
here were no significant differences in in-hospital ischemic
omplications, including death, MI, unplanned revascular-
zation procedures, or their composite, during the initial
ospital stay across the 5 treatment groups (Table 3). There
ere significant differences in the incidence of both
rotocol-defined major and minor bleeding across the 5
roups, with the lowest values consistently in the bivalirudin
onotherapy group (p  0.001 for both comparisons).
imilar findings were noted for 30-day ischemic and bleed-
ng end points (data not shown).
Although anticoagulation costs were lowest with heparin
atheterization laboratory GPI compared with the other
egimens (cost savings ranging from $381 to $1,022/
atient), costs for hospital room and ancillary services as
ell as physician costs were lowest for patients assigned to
ivalirudin monotherapy. Overall costs of the index hospital
tay differed significantly across the treatment groups (p 
.001 for the 5-way comparison), and both mean and
edian costs were lowest with bivalirudin monotherapy
mean $13,844, median $11,372) compared with heparin 
atheterization laboratory GPI (mean $14,028, median
11,832) and heparin  upstream GPI (mean $14,416,
edian $12,018) as well as both bivalirudin  GPI groups.
n the basis of bootstrap simulation, the probability that
ivalirudin monotherapy was cost-saving compared with hep-
aseline Clinical Characteristics and Intended Management Strate
Table 1 Baseline Clinical Characteristics and Intended Manage
Heparin
Upstream GPI
(n  1,301)
Cath
Labo
(n 
Age (yrs), mean SD 62 12 6
Male, % 68.9
Diabetes, % 31.5
Current cigarette smoker, % 28.4
Previous MI, % 34.5
Previous PCI, % 48.1
Previous CABG, % 23.3
Biomarker positive, % 51.7
TIMI risk score, %
0–2 12.9
3–4 55.4
5–7 31.6
Time, randomization to catheterization (h)* 4.2 (1.8–16.6) 4.3
Initial management strategy, %
PCI 53.0
CABG 13.2
Medical therapy 33.8
 NS for all comparisons. *Median value and interquartile range.
CABG  coronary artery bypass graft surgery; GPI  glycoprotein IIb/IIIa receptor antagonist; M
nfarction.rin upstream GPI was 94.6%, whereas the probability of sost savings versus heparin  catheterization laboratory
PI was 68.3% (Fig. 1).
Between hospital discharge and 30 days, there were no
ignificant differences in follow-up medical care costs
mong the 5 antithrombotic regimens (Table 3). Cumula-
ive 30-day costs thus remained lowest with bivalirudin
onotherapy compared with regimens including GPI (cost
avings ranging from $123/patient vs. heparin  catheter-
zation laboratory GPI to $938/patient vs. bivalirudin 
pstream GPI, p  0.005 for the overall comparison). On
he basis of bootstrap simulation, the probability of 30-day
ost savings with bivalirudin monotherapy versus heparin 
pstream GPI was 85.3%, whereas the probability of 30-day
ost savings versus heparin  catheterization laboratory
PI was 57.4% (Fig. 2).
eterminants of hospital cost. Independent predictors of
nitial hospital cost (exclusive of study drug costs) according
o multiple linear regression are displayed in Table 4.
n-hospital events, including death, unplanned revascular-
zation procedures, and bleeding complications, were the
trongest correlates of hospital cost. In particular, the
ncremental cost associated with protocol-defined major
leeding was $8,658/event, whereas the incremental costs
ssociated with minor bleeding or a protocol-defined MI
ere $2,282 and $3,388, respectively. Several baseline pa-
ient characteristics, including age, diabetes, and male gen-
er, were also associated with higher initial hospital costs,
hereas prior PCI was associated with a lower cost. Finally,
he initial revascularization strategy selected was also a
t Strategy
Bivalirudin Bivalirudin
Monotherapy
tion
GPI
8)
Upstream GPI
(n  1,325)
Catheterization
Laboratory GPI
(n  1,302)
No GPI
(n  2,615)
62 12 62 12 61 12
67.9 66.9 66.9
30.5 31.1 32.3
29.5 30.4 29.2
32.0 35.1 35.8
46.2 46.5 48.2
21.6 21.2 22.4
49.5 52.5 52.8
12.5 11.3 12.5
58.5 58.6 57.2
29.0 30.1 30.3
.0) 4.0 (1.8–16.5) 4.3 (1.8–17.6) 4.3 (1.7–17.2)
56.8 54.4 54.5
11.6 10.8 11.1
31.6 34.8 34.4
cardial infarction; PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocardialgy
men
eteriza
ratory
1,30
2 12
68.5
32.3
30.7
37.5
48.3
22.0
50.5
13.6
56.5
29.9
(1.8–17
53.7
12.3
34.0
I  myotrong correlate of in-hospital cost, with incremental costs
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Cost-Effectiveness of Bivalirudin in ACS November 25, 2008:1758–68f $29,461 and $8,279 for CABG and PCI, respectively,
ompared with medical therapy alone.
Attributable cost calculations demonstrated that both
ajor and minor bleeding were important drivers of overall
ospital cost for the heparin  GPI groups (Table 4). For
he heparin  upstream GPI group, the attributable cost of
ajor bleeding was $446/patient (i.e., $8,658  0.515),
hereas the attributable cost of minor bleeding was $656/
atient (i.e., $2,282  0.288). For the heparin  catheter-
zation laboratory GPI group, these values were $371/
atient and $518/patient, respectively. By contrast the
ttributable cost of myocardial (re)-infarction for both
eparin  GPI groups was approximately $160/patient.
Similar calculations for the comparison of bivalirudin
onotherapy with heparin  upstream GPI demonstrated
hat reductions in major bleeding accounted for $211/
atient in overall cost offsets (i.e., $8,658  0.0243),
hereas reductions in minor bleeding accounted for an
dditional $266/patient. For the comparison of bivalirudin
ersus heparin  catheterization laboratory GPI, reduced
ajor and minor bleeding accounted for cost offsets of
136/patient and $128/patient, respectively. The remainder
f the observed cost savings was largely explained by minor
mbalances in other in-hospital events and revascularization
rocedures.
ubgroup analyses. The results of pre-specified subgroup
nalyses according to age, gender, biomarker status, creati-
rocedural Resource Use and Cost
Table 2 Procedural Resource Use and Cost
Heparin
Upstream GPI
(n  1,301)
Catheterization
Laboratory GPI
(n  1,308)
Anticoagulant use, %
Bivalirudin 2.5 2.0
GPI 98.2 53.7
LMWH* 42.3 42.5
UFH* 62.7 61.5
Anticoagulant vials†
Bivalirudin 1.3 0.6 1.7 1.4
Eptifibatide 4.5 2.6 4.6 1.6
Tirofiban 1.7 1.7 1.4 0.6
Abciximab 5.3 1.5 3.8 1.2
Anticoagulant costs $896 $2,854
[$725]
$515 $584
[$399]
Index PCI resources‡
Contrast 246 119 248 162
Balloons 1.4 1.3 1.4 1.5
Number of stents, bare-metal 0.2 0.6 0.2 0.7
Number of stents, drug-eluting 1.4 1.1 1.3 1.1
Drug-eluting stent used (%) 83.6 81.0
PCI costs (excluding anticoagulants) $5,979 $3,058
[$4,888]
$6,009 $3,07
[$4,931]
values represent overall comparison across the 5 groups. Values in brackets are medians. *
eparin (LMWH); †among patients receiving the specified anticoagulant; ‡among patients underg
Abbreviations as in Table 1.ine clearance, and Thrombolysis In Myocardial Infarction cisk score failed to reveal any significant interaction between
he magnitude of 30-day cost savings with bivalirudin
onotherapy compared with heparin  either upstream
PI (Fig. 3) or catheterization laboratory GPI (Fig. 4)
p  NS for all interaction tests). Moreover, there was no
vidence that the extent of cost savings with bivalirudin
aried according to the time interval between randomization
nd cardiac catheterization. In fact, for the highest tertile of
ime from randomization to angiography (9.1 h), the
ean cost savings with bivalirudin compared with heparin 
pstream GPI was $1,860/patient (95% confidence interval:
104 to $3,617) and the mean cost savings with bivalirudin
ompared with heparin  catheterization laboratory GPI
as $1,104/patient (95% confidence interval: $2,730 less to
522 more). Although costs differed substantially according
o whether CABG, PCI, or medical therapy was selected as
he initial revascularization strategy, there was also no
vidence of a significant treatment  revascularization
nteraction. Similar findings were observed for subgroup
nalyses of bivalirudin monotherapy compared with either
ivalirudin  GPI regimen (data not shown).
iscussion
or patients with non–ST-segment elevation acute coronary
yndrome (NSTE-ACS) undergoing an early invasive man-
gement strategy, current guidelines recommend use of
Bivalirudin Bivalirudin
Monotherapy
p Value
Upstream GPI
(n  1,325)
Catheterization
Laboratory GPI
(n  1,302)
No GPI
(n  2,615)
97.7 97.6 98.8 0.001
97.7 54.2 7.6 0.001
1.9 2.4 2.7 0.001
13.0 11.2 12.8 0.001
2.0 2.8 2.2 3.9 2.2 2.6 0.001
4.3 2.4 4.5 1.5 4.7 2.5 0.001
1.6 1.4 1.5 0.6 1.6 1.3 0.90
3.0 1.4 3.7 0.9 4.1 1.8 0.12
$1,537 $1,407
[$1,192]
$1,315 $1,727
[$1,000]
$976 $1,139
[$824]
0.001
241 120 240.48 120 245 124 0.71
1.4 1.1 1.4 1.2 1.4 1.2 0.86
0.3 0.7 0.2 0.6 0.3 0.6 0.07
1.3 1.1 1.3 1.0 1.4 1.1 0.82
81.2 81.9 80.7 0.60
$5,962 $2,919
[$4,942]
$5,985 $4,323
[$4,823]
$6,058 $3,131
[$4,883]
0.98
ll proportion of patients received both unfractionated heparin (UFH) and low-molecular weight
I as planned initial revascularization.5
A smaombined anticoagulation and antiplatelet therapy (3). In
Hospital Outcomes, Resource Use, and Costs
Table 3 Hospital Outcomes, Resource Use, and Costs
Heparin  GPI Bivalirudin  GPI
Bivalirudin
Monotherapy
p ValueUpstream GPI
Catheterization
Laboratory GPI Upstream GPI
Catheterization
Laboratory GPI No GPI
Death, % 0.8 0.3 0.7 0.8 0.9 0.35
MI, % 4.7 4.9 5.1 4.8 5.0 0.99
Unplanned revascularization, % 0.9 0.8 1.1 1.6 0.9 0.22
PCI 0.6 0.5 0.6 1.3 0.7 0.09
CABG 0.3 0.3 0.5 0.3 0.2 0.84
Death or MI, % 5.4 5.0 5.5 5.5 5.6 0.96
Death, MI, or unplanned revascularization, % 5.9 5.6 6.0 6.6 6.0 0.87
Major bleeding, % 5.1 4.3 6.1 3.7 2.7 0.001
Minor bleeding, % 28.2 20.9 27.5 22.8 14.1 0.001
Transfusion, % 8.4 7.0 9.1 5.8 6.9 0.007
Length of stay, days 3.7 3.5 [2.0] 3.6 3.4 [2.0] 3.5 3.5 [2.0] 3.3 3.2 [2.0] 3.4 3.3 [2.0] 0.02
ICU length of stay, days 1.3 2.7 [0] 1.2 2.3 [0] 1.2 2.0 [0] 1.2 2.6 [0] 1.2 2.5 [0] 0.10
Costs
Anticoagulant medications $896 $2,854 [$725] $515 $583 [$399] $1,537 $1,407 [$1,192] $1,315 $1,727 [$1,000] $976 $1,139 [$824] 0.001
Catheterization laboratory procedures $3,207 $3,775 [$2,672] $3,243 $3,793 [$2,672] $3,399 $3,714 [$3,528] $3,335 $4,435 [$2,887] $3,336 $3,846 [$2,824] 0.58
Hospital room and ancillary services $8,705 $12,301 [$4,757] $8,610 $12,149 [$4,757] $8,244 $11,284 [$4,329] $7,933 $10,139 [$4,329] $7,887 $10,610 [$4,329] 0.04
Physician fees $2,071 $2,620 [$1,486] $1,957 $2,278 [$1,486] $1,958 $2,224 [$1,486] $1,798 $2,115 [$1,430] $1,867 $2,218 [$1,431] 0.02
Total cost for initial hospital stay $14,416 $11,944 [$11,443] $14,028 $12,069 [$11,377] $14,925 $11,652 [$12,058] $14,153 $11,321 [$11,765] $13,844 $11,621 [$10,927] 0.001
Discharge to 30 days cost $767 $3,254 [$0] $856 $3,370 [$0] $774 $3,230 [$0] $945 $3,691 [$0] $917 $3,610 [$0] 0.658
Total 30-day cost $15,183 $12,646 [$12,018] $14,884 $12,576 [$11,832] $15,699 $12,094 [$12,649] $15,099 $11,991 [$12,304] $14,761 $12,347 [$11,372] 0.005
Values in brackets are medians.
ICU  intensive care unit, other abbreviations as in Table 1.
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Cost-Effectiveness of Bivalirudin in ACS November 25, 2008:1758–68he ACUITY trial, the use of bivalirudin monotherapy—
tarted before cardiac catheterization—was found to be
tatistically noninferior to either heparin GPI or bivaliru-
inGPI for the prevention of ischemic complications and
uperior to both GPI-containing regimens for prevention of
leeding complications (1). More recently, the ACUITY
nvestigators reported similar rates of 1-year mortality
cross the alternative antithrombotic regimens as well (8).
iven these comparable rates of major ischemic events,
ther considerations including cost might provide further
mportant insight into the optimal antithrombotic regimen.
Figure 1 Bootstrap Analysis of Index Hospital Stay Costs
Performance of 1,000 bootstrap replicates indicates a 94.6% probability of cost s
lecular weight heparin) with upstream glycoprotein IIb/IIIa receptor inhibition (GPI)
pared with heparin (unfractionated or low molecular weight heparin) and catheteriz
Figure 2 Bootstrap Analysis of 30-Day Costs
Performance of 1,000 bootstrap replicates indicates an 85.3% probability of cost
molecular weight heparin) with upstream GPI (yellow line) and a 57.4% probability
low molecular weight heparin) and catheterization laboratory-initiated GPI (black linThis prospective economic analysis shows that, during
he initial hospital stay, use of bivalirudin monotherapy was
ssociated with net cost savings of approximately $600/
atient compared with heparin  routine upstream GPI
nd approximately $200/patient compared with heparin 
atheterization laboratory GPI for patients undergoing PCI.
hese cost savings were obtained despite similar or higher
osts for antithrombotic therapy and were explained mainly
y reductions in bleeding complications and LOS. In
ontrast, costs for regimens involving both bivalirudin 
PI (which provided no significant clinical benefits) were
with bivalirudin monotherapy compared with heparin (unfractionated or low-mo-
line) and a 68.3% probability of lower cost with bivalirudin monotherapy com-
aboratory (cath lab)-initiated GPI (black line).
s with bivalirudin monotherapy compared with heparin (unfractionated or low
er cost with bivalirudin monotherapy compared with heparin (unfractionated or
breviations as in Figure 1.avings
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November 25, 2008:1758–68 Cost-Effectiveness of Bivalirudin in ACSonsistently higher than those for either bivalirudin mono-
herapy or heparin  catheterization laboratory GPI. The
esults were generally similar (although slightly attenuated)
t 30 days and were consistent across a broad range of
re-specified patient subsets. There were no statistically
ignificant differences in costs in the interval between
ischarge and 30 days, indicating that minor differences in
ollow-up costs were likely due to chance alone.
These findings represent the first prospective economic
valuation of alternative antithrombotic strategies for
STE-ACS in patients undergoing early invasive manage-
ent and suggest that bivalirudin monotherapy might
rovide both a clinical advantage (in terms of reduced major
nd minor bleeding complications, thrombocytopenia, and
ewer blood product transfusions) as well as a modest
conomic advantage over current standard approaches.
In addition to quantifying the extent of cost savings
ssociated with the use of bivalirudin, this study provides
mportant insight into those factors that determine the cost
f hospital stay for patients with NSTE-ACS. As demon-
trated by our regression analysis (Table 4), on a “per event”
asis, the most important factors increasing costs among
atients undergoing early invasive management for ACS are
omplications, including unplanned revascularization,
eath, and major bleeding. In contrast, when the frequency
f complications was also considered, the attributable costs
f death or unplanned revascularization were both $200/
atient due to their rare occurrence, whereas major and
inor bleeding were the most costly complications on a
per-patient” basis, because these were far more frequent.
or example, for patients receiving heparin  upstream
ndependent Predictors of Initial Hospital Cost and Attributable Co
Table 4 Independent Predictors of Initial Hospital Cost and Att
Event or Patient Characteristic Estimated Cost* 95% Confidence Inter
In-hospital events
Death $9,061 ($4,451 to $13,670)
MI $3,388 ($1,746 to $5,030)
Major bleed (protocol defined) $8,658 ($6,789 to $10,527)
Minor bleed $2,282 ($1,325 to $3,238)
Unplanned PCI or CABG $12,293 ($9,225 to $15,362)
Patient characteristics
Age (yrs) $56 ($24 to $88)
Gender (male) $705 ($106 to $1,516)
Diabetes $896 ($86 to $1,706)
Previous PCI ($1,106) ($1,863 to$350)
Initial management strategy
PCI $8,279 ($7,439 to $9,118)
CABG $29,461 ($28,130 to $30,792)
Total cost of complications
alues in the “estimated cost” column represent the individual regression coefficients from
utcomes/complications. “Attributable cost” values represent the product of the estimated cost/eve
or the group (for continuous variables, like age). *Estimated cost of each complication on the ba
Abbreviations as in Table 1.PI, the attributable costs of major and minor bleeding mere $446/patient and $656/patient and accounted for
pproximately 8% of the total cost of the hospital stay. The
ndings were similar for the heparin  catheterization
aboratory GPI group. By reducing the frequency of both
ajor and minor bleeding complications by 33% to 50%,
ivalirudin monotherapy thus led to substantial hospital cost
avings compared with either heparin  GPI-based treat-
ent strategy. These savings reflect not only the shorter
ength of stay observed with bivalirudin monotherapy but
lso likely relate to reduced intensity of ancillary testing and
hysician services associated with avoidance of these
esource-intensive complications. Nevertheless, it is impor-
ant to note that reduced bleeding did not fully account for
he entirety of cost savings observed in the ACUITY trial.
o some extent, it is likely that additional factors, including
inor imbalances in baseline patient characteristics and
anagement strategies as well as other advantages of biva-
irudin monotherapy (e.g., fixed dosing without need for
onitoring or dose adjustment, fewer intravenous lines, and
horter infusion durations), might have also contributed to
ost savings in this open-label trial.
omparison with previous studies. Few previous studies
ave directly compared the costs of care for patients receiv-
ng alternative antithrombotic regimens in the setting of
STE-ACS—particularly for patients undergoing an early
nvasive management strategy. Mark et al. (9) performed a
rospective economic analysis alongside the PURSUIT
Platelet IIb/IIIa in Unstable Angina: Receptor Suppression
sing Integrelin Therapy) trial comparing heparin  epti-
batide versus heparin alone for patients with NSTE-ACS
ndergoing both conservative and early invasive manage-
able Costs
Heparin 
Upstream
GPI Group
Heparin 
Catheterization
Laboratory
GPI Group
Attributable Cost
in Heparin 
Upstream
GPI Group
Attributable Cost
in Heparin 
Catheterization
Laboratory
GPI Group
0.77% 0.31% $70 $28
4.69% 4.89% $159 $166
5.15% 4.28% $446 $371
28.75% 22.71% $656 $518
1.15% 0.99% $142 $122
62.1 61.6 $3,477 $3,448
68.87% 68.50% $486 $483
31.45% 32.31% $282 $289
48.07% 48.31% ($532) ($534)
52.99% 53.75% $4,387 $4,450
13.21% 12.28% $3,892 $3,617
$1473 $1205
ar regression model relating total in-hospital costs with patient characteristics as well as
either the proportion of patients with the specific attribute (for binary covariates) or themean value
linear regression model of initial costs among patients with billing data (model R2  0.51).sts
ribut
val
a line
nt andent. They found that, despite the additional cost of
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Cost-Effectiveness of Bivalirudin in ACS November 25, 2008:1758–681,217/patient, use of eptifibatide was associated with an
mprovement in life expectancy of 0.11 years and a favorable
ncremental cost-effectiveness ratio of $16,491/year of life
ained. Glaser et al. (10) used a decision-analytic model to
ompare the cost-effectiveness of heparin upstream use of
small molecule GPI with heparin  catheterization
aboratory use of the monoclonal antibody abciximab. They
ound that the upstream GPI strategy was clinically superior
nd was associated with a favorable cost-effectiveness ratio
f $18,000/year of life gained. Although these studies do
ot relate directly to our study, both provide indirect
upport for the consideration of heparin upstream GPI as
he primary reference strategy for our empirical comparison.
The only previous study to directly compare the costs of
ivalirudin monotherapy with heparin  GPI was the
EPLACE-2 (Randomized Evaluation in PCI Linking
ngiomax to Reduced Clinical Events) trial (11). In the
EPLACE-2 trial, use of bivalirudin with provisional GPI
ersus heparin  routine GPI for patients undergoing
onemergent PCI was associated with a cost savings of
pproximately $400/patient during both the index hospital
tay and at 30 days. Although our overall findings of cost
Figure 3 Stratified Analyses of Aggregate 30-Day Costs by Tre
The graph indicates the mean difference in costs between the bivalirudin and hep
receptor inhibitor (GPI) (black squares) along with the associated 95% confidence
treatment effect represents the most meaningful treatment effect for these subgroavings with bivalirudin are similar to the results of the AEPLACE-2 trial, there are several important differences
etween the 2 studies. First, the population of the
EPLACE-2 trial consisted entirely of stable or low-risk
CS patients undergoing PCI. In contrast, the ACUITY
rial was conducted among patients with moderate- and
igh-risk ACS who were undergoing a combination of
edical therapy, PCI, and bypass surgery. Moreover in the
EPLACE-2 trial, the cost savings achieved with bivaliru-
in compared with heparin  GPI, both initiated in the
atheterization laboratory, were due to a combination of
ower study drug costs as well as reduced bleeding compli-
ations. In contrast, when compared with heparin  either
pstream or catheterization laboratory-initiated GPI in the
CUITY trial, bivalirudin initiated before cardiac catheter-
zation was actually associated with higher drug acquisition
osts, which were still more than offset by in-hospital cost
avings. These findings reflect the fact that the incremental
osts of major and minor bleeding were actually higher in
he ACUITY than in the REPLACE-2 trial. Although the
recise explanation for these differences is unknown, one
ossibility is that the higher cost/bleeding event in the
nt Group According to Pre-Specified Patient Characteristics
nfractionated or low molecular weight heparin)  upstream glycoprotein IIb/IIIa
al (bars). No interaction p values were significant, indicating that the overall
ll p values for interaction 0.05).atme
arin (u
interv
ups (aCUITY trial reflects the greater complexity and underly-
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November 25, 2008:1758–68 Cost-Effectiveness of Bivalirudin in ACSng disease severity of the ACS patient population, partic-
larly when identified before coronary angiography.
linical implications. The results of our economic study,
n concert with the findings of reduced bleeding and similar
ates of early and late ischemia and mortality, support the
se of bivalirudin monotherapy before cardiac catheteriza-
ion as a valid if not the preferred antithrombotic strategy
or patients with ACS undergoing an early invasive strategy.
t is important to note that the economic benefits of
ivalirudin monotherapy did depend to some extent on the
omparator strategy. When compared with the “gold stan-
ard” strategy of heparin  upstream GPI, bivalirudin
onotherapy was associated with a cost savings of approx-
mately $600/patient during the initial hospital stay and
pproximately $400/patient at 30 days, and bootstrap sim-
lation demonstrated that the probability of net cost savings
ith bivalirudin was 95% in hospital and 85% at 30
ays. Given the substantial interindividual variability in
osts, however, the comparison versus heparin  catheter-
zation laboratory GPI was less definitive. Although, on
verage, bivalirudin monotherapy was associated with the
owest costs at both hospital discharge and 30 days, bootstrap
Figure 4 Stratified Analyses of Aggregate 30-Day Costs by Tre
The graph indicates the mean difference in costs between the bivalirudin and h
initiated GPI (black squares) along with the associated 95% confidence interval (b
subgroups (all p values for interaction 0.05). CrCI  creatinine clearance; TRS imulation demonstrated that, compared with heparin  aatheterization laboratory GPI, the confidence limits on
hese cost differences were wide, and the probabilities of net
ost savings in hospital and at 30 days were only 68% and
7%, respectively. Nonetheless, these findings should be
onsidered in the context of both the ACUITY Timing trial
esults, where formal criteria for noninferiority were not met
or the comparison of catheterization laboratory-initiated
PI versus upstream GPI (in terms of ischemic events)
12), as well recent follow-up data that demonstrated
irtually identical mortality rates at 1 year across all 5
reatment groups (8).
tudy limitations. We did not collect primary cost data on
ll study participants. Given the size and scope of the trial,
e felt that such an effort would have been relatively
nefficient. Instead, we elected to collect primary cost data
n a large subset of patients (2,500) selected at random,
ncluding all patients who experienced a major complica-
ion. As a result, our imputation model was both highly
redictive (model R2  0.75) and stable over a broad range
f alternative sampling scenarios. Second, the results of
his analysis apply only to the U.S. health care system.
iven different drug acquisition costs, treatment patterns,
nt Group According to Pre-Specified Patient Characteristics
(unfractionated or low molecular weight heparin)  catheterization laboratory-
here was no evidence of heterogeneity of treatment effect across any of the
mbolysis In Myocardial Infarction risk score; other abbreviations as in Figure 1.atme
eparin
ars). T
Thrond cost structures, separate analyses will be required to
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Cost-Effectiveness of Bivalirudin in ACS November 25, 2008:1758–68nderstand the economic implications for other health care
ystems.
It is important to note that this study did not include a
ixth arm of heparin alone; as a result, potential comparisons
f our economic results versus such a strategy (which would
ertainly have a very low cost of antithrombotic therapy) are
peculative at best. Although it is possible that much of the
leeding advantage of bivalirudin monotherapy relates to
voidance of GPI, the economic and long-term clinical
onsequences of any increase in ischemic complications
ould need to be considered in such an analysis as well. As
oted previously, the economic analysis of the PURSUIT
rial suggested that the addition of a GPI to heparin
lone was reasonably cost-effective despite an increase in
leeding (cost-effectiveness ratio approximately $19,000/
ife-year gained) (9)—a finding that supports the use of
eparin  GPI as the reference strategy for our economic
nalysis. Whether these findings still apply in the current
ra of aggressive use of upstream clopidogrel for ACS
atients is unknown, however. It is intuitively obvious,
owever, that if heparin alone could yield comparable
ates of both ischemic and bleeding complications to the
egimens examined in this study, it would be an econom-
cally dominant strategy.
Finally, it is important to note that the duration of
upstream” therapy provided in ACUITY was relatively
rief (median of 4.2 h). Nonetheless, it is reassuring that
here was no significant interaction between the duration of
pstream therapy and the economic benefits of bivalirudin;
n fact, the absolute cost savings with bivalirudin were
reatest among the tertile of patients who underwent
oronary angiography 9.1 h after randomization (median
0.7 h in this tertile), reflecting current U.S. practice.
onclusions
mong U.S. patients undergoing an early invasive strategy
or management of NSTE-ACS, treatment with bivalirudin
onotherapy compared with heparin  either upstream or
atheterization laboratory-initiated GPI resulted in similar
ates of ischemic events, reduced bleeding, and shorter
OS. Despite higher drug treatment costs, aggregate hos-
ital and 30-day costs were lowest with bivalirudin mono-
herapy due to a shorter LOS and the prevention of
leeding complications. These findings suggest that biva-
irudin monotherapy is an economically attractive alterna- sive to heparin and GPI in patients with moderate- and
igh-risk NSTE-ACS.
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